{"id":484390,"date":"2021-04-29T08:34:49","date_gmt":"2021-04-29T12:34:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/"},"modified":"2021-04-29T08:34:49","modified_gmt":"2021-04-29T12:34:49","slug":"relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/","title":{"rendered":"Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">April 29, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company&#8217;s lead product candidate, will be presented in six posters at the\u00a02021 Society of Biological Psychiatry (SOBP) Annual Meeting, which is being held virtually <span class=\"xn-chron\">between April 29 and May 1, 2021<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg\" title=\"Relmada Therapeutics Corporate Logo (PRNewsFoto\/Relmada Therapeutics, Inc.)\" alt=\"Relmada Therapeutics Corporate Logo (PRNewsFoto\/Relmada Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Details of the presentations are below:<\/p>\n<p>\n        <b>Date\/Time: <\/b><br \/>\n        <b><br \/>\n          <span class=\"xn-chron\">April 29, 2021<\/span>, from 1:15 \u2013 <span class=\"xn-chron\">2:15 PM ET<\/span><br \/><\/b><br \/>\n        <b>Poster Number:<\/b>\u00a0T142<br \/><b>Title:<\/b>\u00a0Esmethadone\u00a0(REL-1017) Antagonizes NMDA Receptors\u00a0and Reduces Ca2+\u00a0Entry\u00a0in Presence of Quinolinic Acid and\u00a0Gentamicin\u00a0<br \/><b>Session:\u00a0<\/b>Poster Session I<\/p>\n<p>\n        <b>Date\/Time: <\/b><br \/>\n        <b><br \/>\n          <span class=\"xn-chron\">April 29, 2021<\/span>, from 1:15 \u2013 <span class=\"xn-chron\">2:15 PM ET<\/span><br \/><\/b><br \/>\n        <b>Poster Number:<\/b>\u00a0T143<br \/><b>Title:<\/b>\u00a0Esmethadone\u00a0(REL-1017) Reduces Glutamate-Induced\u00a0Currents in NMDA Receptors\u00a0with\u00a0the GluN2D Subunit<br \/><b>Session:\u00a0<\/b>Poster Session I<\/p>\n<p>\n        <b>Date\/Time: <\/b><br \/>\n        <b><br \/>\n          <span class=\"xn-chron\">April 30, 2021<\/span>, from 1:00 \u2013 <span class=\"xn-chron\">2:00 PM ET<\/span><br \/><\/b><br \/>\n        <b>Poster Number:<\/b>\u00a0F136<br \/><b>Title:<\/b>\u00a0Esmethadone\u00a0(REL-1017) Compares\u00a0with\u00a0NMDA\u00a0Receptor Antagonists in FLIPR Ca2+\u00a0Assay\u00a0<br \/><b>Session:\u00a0<\/b>Poster Session II<\/p>\n<p>\n        <b>Date\/Time: <\/b><br \/>\n        <b><br \/>\n          <span class=\"xn-chron\">April 30, 2021<\/span>, from 1:00 \u2013 <span class=\"xn-chron\">2:00 PM ET<\/span><br \/><\/b><br \/>\n        <b>Poster Number:<\/b>\u00a0F137<br \/><b>Title:<\/b>\u00a0Esmethadone\u00a0(REL-1017) Shows Similar Effects to\u00a0Ketamine in Manual Patch Clamp Studies<br \/><b>Session:\u00a0<\/b>Poster Session II<\/p>\n<p>\n        <b>Date\/Time: <\/b><br \/>\n        <b><br \/>\n          <span class=\"xn-chron\">May 1, 2021<\/span>, from 1:30 \u2013 <span class=\"xn-chron\">2:30 PM ET<\/span><br \/><\/b><br \/>\n        <b>Poster Number:<\/b>\u00a0S138<br \/><b>Title:<\/b>\u00a0Esmethadone\u00a0(REL-1017) Restores NMDA Receptor 1\u00a0Subunit Expression in\u00a0an In Vitro Model\u00a0of Glutamatergic\u00a0Excitotoxicity\u00a0<br \/><b>Session:\u00a0<\/b>Poster Session III<\/p>\n<p>\n        <b>Date\/Time: <\/b><br \/>\n        <b><br \/>\n          <span class=\"xn-chron\">May 1, 2021<\/span>, from 1:30 \u2013 <span class=\"xn-chron\">2:30 PM ET<\/span><br \/><\/b><br \/>\n        <b>Poster Number:<\/b>\u00a0S143<br \/><b>Title:<\/b>\u00a0Esmethadone\u00a0(REL-1017) Reduces Glutamate-Induced\u00a0Currents in NMDA Receptors in a Concentration Dependent\u00a0Manner<br \/><b>Session:\u00a0<\/b>Poster Session III<\/p>\n<p>\n        <b>About REL-1017<\/b>\n      <\/p>\n<p>REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is entering late-stage studies as an adjunctive treatment for MDD in adults.\u00a0 Our clinical program for REL-1017 will evaluate its potential as the first rapid-acting, oral, once-daily antidepressant treatment.\u00a0 In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.\u00a0 The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies. In <span class=\"xn-chron\">April 2017<\/span>, the FDA granted Fast Track designation for REL-1017 for the adjunctive treatment of major depressive disorder.<\/p>\n<p>\n        <b>About Relmada Therapeutics, Inc. <\/b>\n      <\/p>\n<p>Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada&#8217; s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. Learn more at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3146592-1&amp;h=3766287879&amp;u=http%3A%2F%2Fwww.relmada.com%2F&amp;a=www.relmada.com\" rel=\"nofollow noopener\">www.relmada.com<\/a>. <\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;will,&#8221; &#8220;will likely result,&#8221; &#8220;will continue,&#8221; &#8220;plans to,&#8221; &#8220;potential,&#8221; &#8220;promising,&#8221; and similar expressions. These statements are based on management&#8217;s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading &#8220;Risk Factors&#8221; set forth in the Company&#8217;s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.<\/p>\n<p>\n        <b>Investor Contact: <br \/><\/b><br \/>\n        <span class=\"xn-person\">Tim McCarthy<\/span><br \/>\n        <br \/>LifeSci Advisors <br \/>212-915-2564 <br \/><a target=\"_blank\" href=\"mailto:Tim@LifeSciAdvisors.com\" rel=\"nofollow noopener\">Tim@LifeSciAdvisors.com<\/a><\/p>\n<p>\n        <b>Media Inquiries: <br \/><\/b>FischTank PR<br \/><a target=\"_blank\" href=\"mailto:Relmada@FischTankPR.com\" rel=\"nofollow noopener\">Relmada@FischTankPR.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH60509&amp;sd=2021-04-29\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting-301280188.html\">http:\/\/www.prnewswire.com\/news-releases\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting-301280188.html<\/a><\/p>\n<p>SOURCE  Relmada Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PH60509&amp;Transmission_Id=202104290830PR_NEWS_USPR_____PH60509&amp;DateId=20210429\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK, April 29, 2021 \/PRNewswire\/ &#8212;\u00a0Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company&#8217;s lead product candidate, will be presented in six posters at the\u00a02021 Society of Biological Psychiatry (SOBP) Annual Meeting, which is being held virtually between April 29 and May 1, 2021. Details of the presentations are below: Date\/Time: April 29, 2021, from 1:15 \u2013 2:15 PM ET Poster Number:\u00a0T142Title:\u00a0Esmethadone\u00a0(REL-1017) Antagonizes NMDA Receptors\u00a0and Reduces Ca2+\u00a0Entry\u00a0in Presence of Quinolinic Acid and\u00a0Gentamicin\u00a0Session:\u00a0Poster Session I Date\/Time: April 29, 2021, from 1:15 \u2013 2:15 PM ET Poster Number:\u00a0T143Title:\u00a0Esmethadone\u00a0(REL-1017) Reduces Glutamate-Induced\u00a0Currents in NMDA Receptors\u00a0with\u00a0the GluN2D SubunitSession:\u00a0Poster Session I Date\/Time: April 30, 2021, from &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-484390","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, April 29, 2021 \/PRNewswire\/ &#8212;\u00a0Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company&#8217;s lead product candidate, will be presented in six posters at the\u00a02021 Society of Biological Psychiatry (SOBP) Annual Meeting, which is being held virtually between April 29 and May 1, 2021. Details of the presentations are below: Date\/Time: April 29, 2021, from 1:15 \u2013 2:15 PM ET Poster Number:\u00a0T142Title:\u00a0Esmethadone\u00a0(REL-1017) Antagonizes NMDA Receptors\u00a0and Reduces Ca2+\u00a0Entry\u00a0in Presence of Quinolinic Acid and\u00a0Gentamicin\u00a0Session:\u00a0Poster Session I Date\/Time: April 29, 2021, from 1:15 \u2013 2:15 PM ET Poster Number:\u00a0T143Title:\u00a0Esmethadone\u00a0(REL-1017) Reduces Glutamate-Induced\u00a0Currents in NMDA Receptors\u00a0with\u00a0the GluN2D SubunitSession:\u00a0Poster Session I Date\/Time: April 30, 2021, from &hellip; Continue reading &quot;Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-29T12:34:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting\",\"datePublished\":\"2021-04-29T12:34:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\\\/\"},\"wordCount\":714,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/168770\\\/relmada_logo_hd_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\\\/\",\"name\":\"Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/168770\\\/relmada_logo_hd_logo.jpg\",\"datePublished\":\"2021-04-29T12:34:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/168770\\\/relmada_logo_hd_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/168770\\\/relmada_logo_hd_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting - Market Newsdesk","og_description":"PR Newswire NEW YORK, April 29, 2021 \/PRNewswire\/ &#8212;\u00a0Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company&#8217;s lead product candidate, will be presented in six posters at the\u00a02021 Society of Biological Psychiatry (SOBP) Annual Meeting, which is being held virtually between April 29 and May 1, 2021. Details of the presentations are below: Date\/Time: April 29, 2021, from 1:15 \u2013 2:15 PM ET Poster Number:\u00a0T142Title:\u00a0Esmethadone\u00a0(REL-1017) Antagonizes NMDA Receptors\u00a0and Reduces Ca2+\u00a0Entry\u00a0in Presence of Quinolinic Acid and\u00a0Gentamicin\u00a0Session:\u00a0Poster Session I Date\/Time: April 29, 2021, from 1:15 \u2013 2:15 PM ET Poster Number:\u00a0T143Title:\u00a0Esmethadone\u00a0(REL-1017) Reduces Glutamate-Induced\u00a0Currents in NMDA Receptors\u00a0with\u00a0the GluN2D SubunitSession:\u00a0Poster Session I Date\/Time: April 30, 2021, from &hellip; Continue reading \"Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-29T12:34:49+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting","datePublished":"2021-04-29T12:34:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/"},"wordCount":714,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/","name":"Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg","datePublished":"2021-04-29T12:34:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/168770\/relmada_logo_hd_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/relmada-therapeutics-announces-poster-presentations-at-the-2021-society-of-biological-psychiatry-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/484390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=484390"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/484390\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=484390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=484390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=484390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}